

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

021187Orig1s021s022

**CLINICAL PHARMACOLOGY AND
BIOPHARMACEUTICS REVIEW(S)**

CLINICAL PHARMACOLOGY REVIEW ADDENDUM

NDA: 021187/s-021 and s-022	Submission Dates: 8/30/2012 (s-021; SDN 791), 12/20/2012 (s-022; SDN 815), 3/12/2013 (s-021; SDN 845), 9/4/2013 (s-021; SDN 877), and 9/19/2013 (s-021; SDN 878)
Brand Name:	NuvaRing [®]
Generic Name:	Etonogestrel / ethinyl estradiol (EE)
Clinical Pharmacology Primary Reviewer:	Chongwoo Yu, PhD
Clinical Pharmacology Secondary Reviewer:	Myong-Jin Kim, PharmD
OCP Division:	Division of Clinical Pharmacology 3 (DCP3)
OND Division:	Division of Bone, Reproductive, and Urologic Products (DBRUP)
Sponsor:	Merck Sharp & Dohme Corp.
Submission Type:	Efficacy Supplement (s-021) and prior approval labeling supplement (s-022)
Formulation, Strengths, and Dosing Regimen:	Vaginal ring; etonogestrel 11.7 mg + EE 2.7 mg; One ring should be inserted in the vagina and remain in place continuously for 3 weeks followed by a 1 week ring-free interval
Indication:	Prevention of pregnancy

The purpose of this addendum is to address the Office of Clinical Pharmacology (OCP)'s final recommendation on Supplements 021 and 022 to NDA 021187.

In the original Clinical Pharmacology review of these supplements to NDA 021187 dated August 30, 2013 in DARRTS, it was stated that "*The Office of Clinical Pharmacology/Division of Clinical Pharmacology III (OCP/DCP-III) has reviewed the efficacy (s-021) and labeling (s-022) supplements submitted to NDA 021187 on August 30, 2012, December 20, 2012, and March 12, 2013. These supplements are acceptable provided that a satisfactory agreement is reached regarding the labeling language.*"

This reviewer finds the Sponsor's proposed product labeling language to be acceptable from the Clinical Pharmacology perspective. The final agreed upon product label between the Sponsor and the DBRUP will be attached to the Approval Letter. There are no outstanding Clinical Pharmacology labeling issues.

1. Recommendation

The OCP/DCP3 finds NDA 021187 acceptable from the Clinical Pharmacology perspective.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

CHONGWOO YU
10/01/2013

MYONG JIN KIM
10/01/2013